Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design

Jonathan W. Riess, Paul K. Paik, David B. Shackelford et al.|Clinical Lung Cancer|2020

Cited by 65